Clinical Trial Update: Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC [Phase 3]

View source ↗

Summary

Phase 3 study comparing individualized sensitivity-directed chemotherapy to dacarbazine in melanoma. Current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• Individualized Sensitivity-Directed Chemotherapy

Snippet

Sponsor: University of Wuerzburg | Conditions: Melanoma | Phase 3 | Status: UNKNOWN